http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008139607-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 |
| filingDate | 2007-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008139607-A |
| titleOfInvention | NEW ANALYSIS FOR DETECTING ANTIBODY ASSOCIATED WITH A CELL MEMBRANE RECEPTOR |
| abstract | 1. Method of competitive analysis for the analysis of a humanized antibody, Campas-1H (alemtuzumab), which is associated with the CD52 receptor of the cell membrane, in a biological sample, the above method includes the steps:! (a) obtaining a sample to be analyzed for the presence of the antibody; ! (b) binding the cells or cell membrane preparations containing the CD52 receptor to the membrane of the filter plate; ! (c) allowing the analyte antibody, Campass-1H, labeled with a detectable label, and the control sample to contact the membrane of the filter plate, thereby allowing the labeled antibody and antibody in the control to compete for binding to the receptors of the cell membrane in the membrane of the filter plate; ! (d) washing unbound reagents through the membrane of the filter plate; ! (e) registering the presence of the label and quantifying Campas-1H (alemtuzumab) by comparison with a calibration standard curve. ! 2. The method of claim 1, wherein the labeled antibody is Campass-1H labeled with a fluorescent label. ! 3. The method of claim 2, wherein the labeled antibody is Campas-1H labeled with europium. ! 4. The method of claim 1, wherein the biological sample is a serum, plasma, whole blood, cerebrospinal fluid, or synovial fluid sample. ! 5. Use of the method according to any of the preceding claims in pharmacokinetic studies or for monitoring purposes. ! 6. Assay kit for humanized antibody, Campas-1H (alemtuzumab) which binds to the cell membrane CD52 receptor, the above assay kit includes! a registerable label attached to the analysis |
| priorityDate | 2006-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23981 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419577787 |
Total number of triples: 19.